Interim18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

FDG PET and risk-adapted therapy in Hodgkinʼs and non-Hodgkinʼs lymphoma

(2009) Yvette L Kasamon et al.   CURRENT OPINION IN ONCOLOGY

Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials

(2009) Michel Meignan et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review

(2009) Teruhiko Terasawa et al.   JOURNAL OF CLINICAL ONCOLOGY

The Case Against Heavy PETing

(2009) Bruce Cheson   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

(2009) E. Itti et al.   JOURNAL OF NUCLEAR MEDICINE

High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens

(2008) H. S. Han et al.   ANNALS OF ONCOLOGY

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

(2008) J. Dupuis et al.   ANNALS OF ONCOLOGY

Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphoma

(2008) Lale Kostakoglu   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Early interim PET scan in Hodgkin lymphoma: Where do we stand?

(2008) Andrea Gallamini et al.   LEUKEMIA & LYMPHOMA